B. Goodwin

发表

Antiretroviral Treatment Switching and Its Association With Economic Outcomes and Adverse Treatment Effects Among Commercially Insured and Medicaid-Enrolled Patients With HIV in the United States

S. Candrilli, Jennifer S. Korsnes, B. Goodwin, 2016, The Annals of pharmacotherapy.

Establishing the clinical and economic benefits of adherence to 5-alpha reductase inhibitors in benign prostatic hyperplasia: an assessment of Medicare and Medicaid patients

B. Goodwin, M. Eaddy, O. Lunacsek, 2012, Expert opinion on pharmacotherapy.

COST ANALYSIS OF RALTEGRAVIR VERSUS ATAZANAVIR/R OR DARUNAVIR/R FOR TREATMENT-NAIVE ADULTS WITH HIV-1 INFECTION IN THE UNITED STATES

B. Goodwin, A. Brogan, A. Davis, 2016 .

Impact on caregivers of adult patients receiving parenteral support for short‐bowel syndrome with intestinal failure: A multinational, cross‐sectional survey

S. Shahraz, B. Goodwin, Kristina S Chen, 2021, JPEN. Journal of parenteral and enteral nutrition.

Documenting the Journey of Patients with Eosinophilic Esophagitis and the Impact of the Disease on Patients and their Caregivers: A Cross-sectional, Qualitative Research Study

B. Goodwin, A. Brooks, G. Harding, 2020, Advances in Therapy.

Evaluation of Recent Trends in Treatment Patterns Among Men With Benign Prostatic Hyperplasia

B. Goodwin, E. Kruep, S. Chaudhari, 2013, American journal of men's health.

Long-Term Treatment of Eosinophilic Esophagitis with Budesonide Oral Suspension.

E. Dellon, G. Falk, R. Fogel, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Disease Burden and Treatment Patterns Associated With Eosinophilic Esophagitis in the United States

B. Goodwin, M. Vera‐Llonch, Mei Lu, 2021, Journal of clinical gastroenterology.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Using Simple and Relative Difference to Interpret Changes in Health-Related Quality-of-Life Scores for Salmeterol, Ipratropium, and Placebo

B. Goodwin, R. Stanford, F. Cox, 2000 .

B. Goodwin, M. Eaddy, M. Runken, 2015, Applied Health Economics and Health Policy.

S802 Persistence Among Patients With Crohn’s Disease Previously Treated With an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent

A. Manceur, B. Goodwin, D. Pilon, 2022, Clinical therapeutics.

Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.

B. Goodwin, M. Eaddy, R. Morlock, 2013, Clinical therapeutics.

293 Asthma-specific quality of life in patients treated with salmeterol or albuterol

S. Wenzel, B. Goodwin, F. Cox, 1996 .

295 The impact of salmeterol versus albuterol on disease specific quality of life in mild to moderate asthmatics

B. Goodwin, W. Lumry, F. Cox, 1996 .